Referências

Principais artigos

American Diabetes Association. Standards of medical care in diabetes - 2021. Diabetes Care. 2021;44(suppl 1):S1-S232.Texto completo external link opens in a new window

Norris JM, Johnson RK, Stene LC. Type 1 diabetes-early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020 Mar;8(3):226-38.Texto completo external link opens in a new windowResumo external link opens in a new window

Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018 Aug 9;41(9):2026-44.Texto completo external link opens in a new windowResumo external link opens in a new window

Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013 Sep 25;310(12):1240-7.Texto completo external link opens in a new windowResumo external link opens in a new window

Nathan DM, Genuth S, Lachin J; The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.Texto completo external link opens in a new windowResumo external link opens in a new window

Artigos de referência

1. American Diabetes Association. Standards of medical care in diabetes - 2021. Diabetes Care. 2021;44(suppl 1):S1-S232.Texto completo external link opens in a new window

2. Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017 Feb;66(2):241-55.Texto completo external link opens in a new windowResumo external link opens in a new window

3. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-74.Texto completo external link opens in a new windowResumo external link opens in a new window

4. Fourlanos S, Perry C, Stein MS, et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006 May;29(5):970-5.Resumo external link opens in a new window

5. Maahs DM, West NA, Lawrence JM, et al. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010 Sep;39(3):481-97.Texto completo external link opens in a new windowResumo external link opens in a new window

6. International Diabetes Federation. Diabetes atlas 9th edition. 2019 [internet publication].Texto completo external link opens in a new window

7. Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Aug 2020 [internet publication].Texto completo external link opens in a new window

8. Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon). 2014;42(12):698-702.Texto completo external link opens in a new windowResumo external link opens in a new window

9. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet. 2000 Mar 11;355(9207):873-6.Resumo external link opens in a new window

10. Adeloye D, Chan KY, Thorley N, et al. Global and regional estimates of the morbidity due to type I diabetes among children aged 0-4 years: a systematic review and analysis. J Glob Health. 2018 Dec;8(2):021101.Texto completo external link opens in a new windowResumo external link opens in a new window

11. Patterson CC, Gyürüs E, Rosenbauer J, et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia. 2012 May 26;55(8):2142-7.Texto completo external link opens in a new windowResumo external link opens in a new window

12. DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med. 2006 Aug;23(8):857-66.Resumo external link opens in a new window

13. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al; SEARCH for Diabetes in Youth Study. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017 Apr 13;376(15):1419-29.Texto completo external link opens in a new windowResumo external link opens in a new window

14. Norris JM, Johnson RK, Stene LC. Type 1 diabetes-early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020 Mar;8(3):226-38.Texto completo external link opens in a new windowResumo external link opens in a new window

15. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep. 2011 Dec;11(6):533-42.Texto completo external link opens in a new windowResumo external link opens in a new window

16. Hyöty H. Viruses in type 1 diabetes. Pediatr Diabetes. 2016 Jul;17 Suppl 22:56-64.Resumo external link opens in a new window

17. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004 Mar 27;328(7442):750-4.Texto completo external link opens in a new windowResumo external link opens in a new window

18. Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol. 2010 May;6(5):279-89.Resumo external link opens in a new window

19. Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001 Nov 3;358(9292):1500-3.Resumo external link opens in a new window

20. Wolden-Kirk H, Overbergh L, Christesen HT, et al. Vitamin D and diabetes: its importance for beta cell and immune function. Mol Cell Endocrinol. 2011 Aug 26;347(1-2):106-20.Resumo external link opens in a new window

21. Hyytinen M, Savilahti E, Virtanen SM, et al; FInnish TRIGR Pilot Study Group. Avoidance of cow's milk-based formula for at-risk infants does not reduce development of celiac disease: a randomized controlled trial. Gastroenterology. 2017 Jul 5;153(4):961-70.e3.Texto completo external link opens in a new windowResumo external link opens in a new window

22. Uusitalo U, Lee HS, Andrén Aronsson C, et al; TEDDY Study Group. Early infant diet and islet autoimmunity in the TEDDY Study. Diabetes Care. 2018 Jan 17;41(3):522-30.Texto completo external link opens in a new windowResumo external link opens in a new window

23. Silvis K, Aronsson CA, Liu X, et al; TEDDY Study Group. Maternal dietary supplement use and development of islet autoimmunity in the offspring: TEDDY study. Pediatr Diabetes. 2018 Dec 9;20(1):86-92.Texto completo external link opens in a new windowResumo external link opens in a new window

24. Kakleas K, Karayianni C, Critselis E, et al. The prevalence and risk factors for coeliac disease among children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2010 Nov;90(2):202-8.Resumo external link opens in a new window

25. Hagopian W, Lee HS, Liu E, et al; TEDDY Study Group. Co-occurrence of type 1 diabetes and celiac disease autoimmunity. Pediatrics. 2017 Oct 10;140(5):e20171305.Texto completo external link opens in a new windowResumo external link opens in a new window

26. Ludvigsson JF, Ludvigsson J, Ekbom A, et al. Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study of children and adolescents. Diabetes Care. 2006 Nov;29(11):2483-8.Texto completo external link opens in a new windowResumo external link opens in a new window

27. Ziegler AG, Hummel M, Schenker M, et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes. 1999 Mar;48(3):460-8.Resumo external link opens in a new window

28. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007 Oct 23;104(43):17040-5.Texto completo external link opens in a new windowResumo external link opens in a new window

29. Niskanen L, Tuomi T, Karjalainen J, et al. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care. 1995 Dec;18(12):1557-65.Resumo external link opens in a new window

30. Garg R, Chaudhuri A, Munschauer F, et al. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke. 2006 Jan;37(1):267-73.Texto completo external link opens in a new windowResumo external link opens in a new window

31. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016 Jun 4;387(10035):2331-9.Texto completo external link opens in a new windowResumo external link opens in a new window

32. Hyttinen V, Kaprio J, Kinnunen L, et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 2003 Apr;52(4):1052-5.Texto completo external link opens in a new windowResumo external link opens in a new window

33. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet. 2004 Nov 6-12;364(9446):1699-700.Resumo external link opens in a new window

34. Lund-Blix NA, Dydensborg Sander S, Størdal K, et al. Infant feeding and risk of type 1 diabetes in two large Scandinavian birth cohorts. Diabetes Care. 2017 May 9;40(7):920-7.Texto completo external link opens in a new windowResumo external link opens in a new window

35. National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. Dec 2020 [internet publication].Texto completo external link opens in a new window

36. Usher-Smith JA, Thompson MJ, Zhu H, et al. The pathway to diagnosis of type 1 diabetes in children: a questionnaire study. BMJ Open. 2015 Mar 17;5(3):e006470.Texto completo external link opens in a new windowResumo external link opens in a new window

37. Cherubini V, Grimsmann JM, Åkesson K, et al. Temporal trends in diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes between 2006 and 2016: results from 13 countries in three continents. Diabetologia. 2020 Aug;63(8):1530-41.Texto completo external link opens in a new windowResumo external link opens in a new window

38. Usher-Smith JA, Thompson MJ, Sharp SJ, et al. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a systematic review. BMJ. 2011 Jul 7;343:d4092.Texto completo external link opens in a new windowResumo external link opens in a new window

39. Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017 May;101(3):587-606.Texto completo external link opens in a new windowResumo external link opens in a new window

40. O'Neal KS, Johnson JL, Panak RL. Recognizing and appropriately treating latent autoimmune diabetes in adults. Diabetes Spectr. 2016 Nov;29(4):249-52.Texto completo external link opens in a new windowResumo external link opens in a new window

41. Pieralice S, Pozzilli P. Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management. Diabetes Metab J. 2018 Dec;42(6):451-64.Texto completo external link opens in a new windowResumo external link opens in a new window

42. Gale EA. The discovery of type 1 diabetes. Diabetes. 2001 Feb;50(2):217-26.Resumo external link opens in a new window

43. Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018 Aug 9;41(9):2026-44.Texto completo external link opens in a new windowResumo external link opens in a new window

44. Pihoker C, Gilliam LK, Ellard S, et al; SEARCH for Diabetes in Youth Study Group. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013 Jun 14;98(10):4055-62.Texto completo external link opens in a new windowResumo external link opens in a new window

45. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011 Aug;34(8):1878-84.Texto completo external link opens in a new windowResumo external link opens in a new window

46. Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: recognition and treatment options. Curr Diab Rep. 2018 Jun 22;18(8):58.Resumo external link opens in a new window

47. Greeley SA, Naylor RN, Philipson LH, et al. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011 Dec;11(6):519-32.Texto completo external link opens in a new windowResumo external link opens in a new window

48. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2010 Jan;95(1):25-33.Texto completo external link opens in a new windowResumo external link opens in a new window

49. Chiang JL, Kirkman MS, Laffel LM, et al; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014 Jul;37(7):2034-54.Texto completo external link opens in a new windowResumo external link opens in a new window

50. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. Dec 2020 [internet publication].Texto completo external link opens in a new window

51. Diabetes UK. Self-monitoring of blood glucose levels for adults with type 1 diabetes. March 2017 [internet publication].Texto completo external link opens in a new window

52. Petrie JR, Peters AL, Bergenstal RM, et al. Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2017 Dec;40(12):1614-21.Texto completo external link opens in a new windowResumo external link opens in a new window

53. Thabit H, Prabhu JN, Mubita W, et al. Use of factory-calibrated real-time continuous glucose monitoring improves time in target and HbA1c in a multiethnic cohort of adolescents and young adults with type 1 diabetes: the MILLENNIALS study. Diabetes Care. 2020 Oct;43(10):2537-43.Texto completo external link opens in a new windowResumo external link opens in a new window

54. Laffel LM, Kanapka LG, Beck RW, et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020 Jun 16;323(23):2388-96.Texto completo external link opens in a new windowResumo external link opens in a new window

55. Agarwal S, Cappola AR. Continuous glucose monitoring in adolescent, young adult, and older patients with type 1 diabetes. JAMA. 2020 Jun 16;323(23):2384-5.Texto completo external link opens in a new windowResumo external link opens in a new window

56. Šoupal J, Petruželková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care. 2020 Jan;43(1):37-43.Texto completo external link opens in a new windowResumo external link opens in a new window

57. Oliver N, Gimenez M, Calhoun P, et al. Continuous glucose monitoring in people with type 1 diabetes on multiple-dose injection therapy: the relationship between glycemic control and hypoglycemia. Diabetes Care. 2020 Jan;43(1):53-8.Texto completo external link opens in a new windowResumo external link opens in a new window

58. Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit. Diabetes Care. 2020 Sep;43(9):2153-60.Texto completo external link opens in a new windowResumo external link opens in a new window

59. Chatterjee S, Davies MJ, Heller S, et al. Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol. 2018 Feb;6(2):130-42.Resumo external link opens in a new window

60. Christie D, Thompson R, Sawtell M, et al. Structured, intensive education maximising engagement, motivation and long-term change for children and young people with diabetes: a cluster randomised controlled trial with integral process and economic evaluation - the CASCADE study. Health Technol Assess. 2014 Mar;18(20):1-202.Texto completo external link opens in a new windowResumo external link opens in a new window

61. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 May;42(5):731-54.Texto completo external link opens in a new windowResumo external link opens in a new window

62. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016 Nov;39(11):2065-79.Texto completo external link opens in a new windowResumo external link opens in a new window

63. Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017 May;5(5):377-90.Resumo external link opens in a new window

64. Aronson R, Brown RE, Li A, et al. Optimal insulin correction factor in post-high-intensity exercise hyperglycemia in adults with type 1 diabetes: the FIT Study. Diabetes Care. 2018 Nov 19;42(1):10-6.Resumo external link opens in a new window

65. Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122.Texto completo external link opens in a new windowResumo external link opens in a new window

66. Misso ML, Egberts KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103.Texto completo external link opens in a new windowResumo external link opens in a new window

67. Beck RW, Buckingham B, Miller K, et al; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009 Nov;32(11):1947-53.Texto completo external link opens in a new windowResumo external link opens in a new window

68. Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013 Sep 25;310(12):1240-7.Texto completo external link opens in a new windowResumo external link opens in a new window

69. Monami M, Lamanna C, Marchionni N, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2010 Dec;47(suppl 1):77-81.Resumo external link opens in a new window

70. Li XL. Multiple daily injections versus insulin pump therapy in patients with type 1 diabetes mellitus: a meta analysis. J Clin Rehabil Tissue Eng Res. 2010;14(46):8722-5.

71. Cummins E, Royle P, Snaith A, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess. 2010 Feb;14(11):iii-iv;xi-xvi;1-181.Texto completo external link opens in a new windowResumo external link opens in a new window

72. Kordonouri O, Hartmann R, Danne T. Treatment of type 1 diabetes in children and adolescents using modern insulin pumps. Diabetes Res Clin Pract. 2011 Aug;93(suppl 1):S118-24.Resumo external link opens in a new window

73. Laranjeira FO, de Andrade KR, Figueiredo AC, et al. Long-acting insulin analogues for type 1 diabetes: an overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS One. 2018 Apr 12;13(4):e0194801.Texto completo external link opens in a new windowResumo external link opens in a new window

74. Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016 Jun 30;(6):CD012161.Texto completo external link opens in a new windowResumo external link opens in a new window

75. Benkhadra K, Alahdab F, Tamhane SU, et al. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2016 Aug 1;55(1):77-84.Resumo external link opens in a new window

76. REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017 Mar 30;356:j1285.Texto completo external link opens in a new windowResumo external link opens in a new window

77. Burdick P, Cooper S, Horner B, et al. Use of a subcutaneous injection port to improve glycemia control in children with type 1 diabetes. Pediatr Diabetes. 2009 Apr;10(2):116-9.Resumo external link opens in a new window

78. Kaiserman K, Rodriguez H, Stephenson A, et al. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus. Endocr Pract. 2012 May-Jun;18(3):418-24.Resumo external link opens in a new window

79. Beck RW, Riddlesworth T, Ruedy K, et al; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017 Jan 24;317(4):371-8.Texto completo external link opens in a new windowResumo external link opens in a new window

80. Benkhadra K, Alahdab F, Tamhane S, et al. Real-time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta-analysis. Clin Endocrinol (Oxf). 2017 Mar;86(3):354-60.Resumo external link opens in a new window

81. Hirsch IB. Clinical review: realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab. 2009 Jul;94(7):2232-8.Texto completo external link opens in a new windowResumo external link opens in a new window

82. Weisman A, Bai JW, Cardinez M, et al. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017 May 19;5(7):501-12.Resumo external link opens in a new window

83. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013 Feb 28;368(9):824-33.Texto completo external link opens in a new windowResumo external link opens in a new window

84. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010 Jul 22;363(4):311-20.Texto completo external link opens in a new windowResumo external link opens in a new window

85. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019 Oct 31;381(18):1707-17.Texto completo external link opens in a new windowResumo external link opens in a new window

86. Raju B, Arbelaez AM, Breckenridge SM, et al. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab. 2006 Jun;91(6):2087-92.Texto completo external link opens in a new windowResumo external link opens in a new window

87. Sturt J, Dennick K, Due-Christensen M, McCarthy K. The detection and management of diabetes distress in people with type 1 diabetes. Curr Diab Rep. 2015 Nov;15(11):101.Texto completo external link opens in a new windowResumo external link opens in a new window

88. Rey Velasco E, Pals RAS, Skinner TC, Grabowski D. Pre-empting the challenges faced in adolescence: A systematic literature review of effects of psychosocial interventions for preteens with type 1 diabetes. Endocrinol Diabetes Metab. 2020 Mar 3;3(2):e00120.Texto completo external link opens in a new windowResumo external link opens in a new window

89. Kodama S, Morikawa S, Horikawa C, et al. Effect of family-oriented diabetes programs on glycemic control: A meta-analysis. Fam Pract. 2019 Jul 31;36(4):387-94.Texto completo external link opens in a new windowResumo external link opens in a new window

90. McCance DR, Casey C. Type 1 Diabetes in Pregnancy. Endocrinol Metab Clin North Am. 2019 Sep;48(3):495-509.Texto completo external link opens in a new windowResumo external link opens in a new window

91. Feldman AZ, Brown FM. Management of Type 1 Diabetes in Pregnancy. Curr Diab Rep. 2016 Aug;16(8):76.Texto completo external link opens in a new windowResumo external link opens in a new window

92. Tinker SC, Gilboa SM, Moore CA, et al. Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011. Am J Obstet Gynecol. 2020 Feb;222(2):176.e1-176.Texto completo external link opens in a new windowResumo external link opens in a new window

93. Mathiesen ER, Hod M, Ivanisevic M, et al; Detemir in Pregnancy Study Group. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012 Oct;35(10):2012-7.Texto completo external link opens in a new windowResumo external link opens in a new window

94. Feig DS, Donovan LE, Corcoy R, et al; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017 Nov 25;390(10110):2347-59. [Erratum in: Lancet. 2017 Nov 25;390(10110):2346.]Texto completo external link opens in a new windowResumo external link opens in a new window

95. Lv S, Wang J, Xu Y. Safety of insulin analogs during pregnancy: a meta-analysis. Arch Gynecol Obstet. 2015 Oct;292(4):749-56.Texto completo external link opens in a new windowResumo external link opens in a new window

96. Farrar D, Tuffnell DJ, West J, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2016 Jun 7;(6):CD005542.Texto completo external link opens in a new windowResumo external link opens in a new window

97. Feig DS, Corcoy R, Donovan LE, et al. Pumps or multiple daily injections in pregnancy involving type 1 diabetes: a prespecified analysis of the CONCEPTT randomized trial. Diabetes Care. 2018 Oct 16;41(12):2471-9.Texto completo external link opens in a new windowResumo external link opens in a new window

98. Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag. 2006;2(3):203-12.Texto completo external link opens in a new windowResumo external link opens in a new window

99. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008 Oct 30;359(18):1909-20.Texto completo external link opens in a new windowResumo external link opens in a new window

100. Xin GLL, Khee YP, Ying TY, et al. Current Status on Immunological Therapies for Type 1 Diabetes Mellitus. Curr Diab Rep. 2019 Mar 23;19(5):22.Texto completo external link opens in a new windowResumo external link opens in a new window

101. Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care. 2009 Oct;32(10):1769-82.Texto completo external link opens in a new windowResumo external link opens in a new window

102. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011 Aug 6;378(9790):487-97.Texto completo external link opens in a new windowResumo external link opens in a new window

103. Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013 Nov;62(11):3901-8.Texto completo external link opens in a new windowResumo external link opens in a new window

104. Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019 Aug 15;381(7):603-13.Texto completo external link opens in a new windowResumo external link opens in a new window

105. Vantyghem MC, de Koning EJP, Pattou F, Rickels MR. Advances in β-cell replacement therapy for the treatment of type 1 diabetes. Lancet. 2019 Oct 5;394(10205):1274-85.Texto completo external link opens in a new windowResumo external link opens in a new window

106. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28;355(13):1318-30.Texto completo external link opens in a new windowResumo external link opens in a new window

107. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005 Jul;54(7):2060-9.Texto completo external link opens in a new windowResumo external link opens in a new window

108. US Food and Drug Administration. FDA approves Afrezza to treat diabetes. Jun 2014 [internet publication].Texto completo external link opens in a new window

109. Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 2008 Nov;57(11):2883-8.Texto completo external link opens in a new windowResumo external link opens in a new window

110. Vella S, Buetow L, Royle P, et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010 May;53(5):809-20.Texto completo external link opens in a new windowResumo external link opens in a new window

111. DeGeeter M, Williamson B. Alternative agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors. J Pharm Pract. 2016 Apr;29(2):144-59.Resumo external link opens in a new window

112. Petrie JR, Chaturvedi N, Ford I, et al; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609.Texto completo external link opens in a new windowResumo external link opens in a new window

113. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017 Dec 14;377(24):2337-48.Texto completo external link opens in a new windowResumo external link opens in a new window

114. Hampp C, Swain RS, Horgan C, et al. Use of sodium-glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis. Diabetes Care. 2020 Jan;43(1):90-7.Texto completo external link opens in a new windowResumo external link opens in a new window

115. Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017 Mar 9;7:44128.Texto completo external link opens in a new windowResumo external link opens in a new window

116. Taylor SI, Blau JE, Rother KI, et al. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol. 2019 Dec;7(12):949-58.Texto completo external link opens in a new windowResumo external link opens in a new window

117. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Sep 14;5(11):864-76.Resumo external link opens in a new window

118. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018 Oct 23;41(12):2552-9.Resumo external link opens in a new window

119. Mathieu C, Dandona P, Gillard P, et al; DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care. 2018 Jul 19;41(9):1938-46.Texto completo external link opens in a new windowResumo external link opens in a new window

120. National Institute for Health and Care Excellence. Dapagliflozin with insulin for treating type 1 diabetes (TA597). Feb 2020 [internet publication].Texto completo external link opens in a new window

121. Danne T, Cariou B, Buse JB, et al. Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem Program. Diabetes Care. 2019 May;42(5):919-30.Resumo external link opens in a new window

122. Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study. Diabetes Care. 2018 Jun 24;41(9):1970-80.Texto completo external link opens in a new windowResumo external link opens in a new window

123. Danne T, Cariou B, Banks P, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study. Diabetes Care. 2018 Jun 24;41(9):1981-90.Texto completo external link opens in a new windowResumo external link opens in a new window

124. Musso G, Gambino R, Cassader M, et al. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019 Apr 9;365:l1328.Texto completo external link opens in a new windowResumo external link opens in a new window

125. National Institute for Health and Care Excellence. Sotagliflozin with insulin for treating type 1 diabetes – guidance (TA622). February 2020 [internet publication].Texto completo external link opens in a new window

126. Peters AL, McGuire DK, Danne T, et al. Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: a pooled analysis of the inTandem 1 and 2 Studies. Diabetes Care. 2020 Nov;43(11):2713-20.Texto completo external link opens in a new windowResumo external link opens in a new window

127. Janzen KM, Steuber TD, Nisly SA. GLP-1 agonists in type 1 diabetes mellitus. Ann Pharmacother. 2016 Aug;50(8):656-65.Resumo external link opens in a new window

128. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010 May;59(5):1244-53.Resumo external link opens in a new window

129. Nathan DM, Genuth S, Lachin J; The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.Texto completo external link opens in a new windowResumo external link opens in a new window

130. Pop-Busui RL, Low PA, Waberski BH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Circulation. 2009 Jun 9;119(22):2886-93.Texto completo external link opens in a new windowResumo external link opens in a new window

131. Nathan DM, Zinman B, Cleary PA, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16.Texto completo external link opens in a new windowResumo external link opens in a new window

132. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53.Texto completo external link opens in a new windowResumo external link opens in a new window

133. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC Study 30-year follow-up. Diabetes Care. 2016 May;39(5):686-93.Texto completo external link opens in a new windowResumo external link opens in a new window

134. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010 May;33(5):1090-6.Texto completo external link opens in a new windowResumo external link opens in a new window

135. Gagnum V, Stene LC, Jenssen TG, et al. Causes of death in childhood-onset type 1 diabetes: long-term follow-up. Diabet Med. 2017 Jan;34(1):56-63.Resumo external link opens in a new window

136. American Diabetes Association. Hyperglycemic crises in diabetes. Diabetes Care. 2004 Jan;27(suppl 1):S94-102.Texto completo external link opens in a new windowResumo external link opens in a new window

137. Thieu VT, Mitchell BD, Varnado OJ, Frier BM. Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon. Diabetes Obes Metab. 2020 Apr;22(4):469-79.Texto completo external link opens in a new windowResumo external link opens in a new window

138. Koye DN, Shaw JE, Reid CM, et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabet Med. 2017 Mar 9;34(7):887-901.Resumo external link opens in a new window

139. Helve J, Sund R, Arffman M, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. Diabetes Care. 2017 Dec 20;41(3):434-9.Texto completo external link opens in a new windowResumo external link opens in a new window

140. Perkins BA, Bebu I, de Boer IH, et al. Risk factors for kidney disease in type 1 diabetes. Diabetes Care. 2019 Mar 4 [Epub ahead of print].Resumo external link opens in a new window

141. Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs. 2006;66(17):2213-34.Resumo external link opens in a new window

142. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993 Apr;43(4):817-24. [Erratum in: Neurology. 1993 Nov;43(11):2345.]Resumo external link opens in a new window

143. Braffett BH, Dagogo-Jack S, Bebu I, et al. Association of insulin dose, cardiometabolic risk factors, and cardiovascular disease in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC Study. Diabetes Care. 2019 Feb 6;42(4):657-64.Texto completo external link opens in a new windowResumo external link opens in a new window

144. Bebu I, Braffett BH, Orchard TJ, et al. Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC study. Diabetes Care. 2019 Jul;42(7):1284-9.Texto completo external link opens in a new windowResumo external link opens in a new window

145. Guo J, Brooks MM, Muldoon MF, et al. Optimal blood pressure thresholds for minimal coronary artery disease risk in type 1 diabetes. Diabetes Care. 2019 Sep;42(9):1692-9.Texto completo external link opens in a new windowResumo external link opens in a new window

146. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. Circulation. 2019 Jun 18;139(25):e1162-77.Texto completo external link opens in a new windowResumo external link opens in a new window

147. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-85.Texto completo external link opens in a new windowResumo external link opens in a new window

148. Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012 Oct;142 Suppl:S8-21.Texto completo external link opens in a new windowResumo external link opens in a new window

149. Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001 Jun;24(6):1069-78.Texto completo external link opens in a new windowResumo external link opens in a new window

150. Trief PM, Foster NC, Chaytor N, et al. Longitudinal changes in depression symptoms and glycemia in adults with type 1 diabetes. Diabetes Care. 2019 Jul;42(7):1194-201.Texto completo external link opens in a new windowResumo external link opens in a new window

151. Delamater AM, de Wit M, McDarby V, et al; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Psychological care of children and adolescents with type 1 diabetes. Pediatr Diabetes. 2014 Sep;15 Suppl 20:232-44.Texto completo external link opens in a new windowResumo external link opens in a new window

152. Buchberger B, Huppertz H, Krabbe L, et al. Symptoms of depression and anxiety in youth with type 1 diabetes: A systematic review and meta-analysis. Psychoneuroendocrinology. 2016 Aug;70:70-84.Texto completo external link opens in a new windowResumo external link opens in a new window

O uso deste conteúdo está sujeito ao nosso aviso legal